Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2009 Results
Date:4/29/2009

Circadian Rhythm Sleep Disorders.

FINANCIAL DETAILS

* Operating Expenses. First quarter 2009 R&D expenses of $2.3 million,

consisted primarily of $0.5 million of salaries and benefits and

$0.2 million of non-cash stock based compensation costs for R&D

personnel, as well as $0.8 million of regulatory consultant fees,

and $0.2 million of pre-clinical work. This compares to

$3.6 million for the fourth quarter of 2008 and $11.1 million for

the first quarter of 2008. The decrease in R&D expenses in the first

quarter of 2009 relative to the fourth quarter of 2008 is primarily

due to the decrease in regulatory consulting and other professional

fees related to iloperidone. The decrease in R&D expenses in the

first quarter of 2009 relative to the first quarter of 2008 is

primarily due to the completion in the second quarter of 2008 of the

Phase III clinical trial for tasimelteon in chronic primary

insomnia.

General and administrative (G&A) expenses of $4.2 million for the

first quarter of 2009 consisted primarily of $0.5 million of

salaries and benefits and $2.1 million of non-cash stock based

compensation costs for G&A personnel, as well as $0.7 million of

legal fees, and $0.2 million of insurance costs. This compares to

$4.1 million for the fourth quarter of 2008 and $9.0 million for the

first quarter of 2008. The increase in G&A expenses in the first

quarter of 2009 relative to the fourth quarter of 2008 is primarily

due to an increase in legal and professional fees offset by a

decrease in stock-based compensation costs. The decrease in
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
6. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
8. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
9. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
10. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
11. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , ... June 29, 2015 , ... ... B2. Under the terms of the agreement, MediVet will acquire the rights to ... (UCMSCs). MB-007 is currently in pre-clinical development as a potential next-generation treatment for ...
(Date:6/29/2015)... June 29, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... "Pete" Petit, has been awarded the Lifetime Achievement Award ... Program. The Entrepreneur Of The Year ...
(Date:6/29/2015)... SAN FRANCISCO, Calif. , June 29, 2015 /PRNewswire/ ... molecular diagnostics company pioneering the field of molecular cytology, ... Bay Area News Group,s prestigious Top Workplaces list for ... selects Top Workplace winners based solely on an annual ... are humbled and honored that the degree to which ...
(Date:6/26/2015)... June 26, 2015   Aratana Therapeutics, ... pet therapeutics company focused on the licensing, ... for companion animals, today announced positive results ... capromorelin (AT-002), the company,s innovative therapeutic for ... small molecule that mimics ghrelin, the naturally ...
Breaking Biology Technology:MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5
... Beck and C. Schmidt, Varian, Inc. , ... Marijuana is one of the most commonly used illegal recreational drugs in ... is tetrahydrocannabinol or THC. Toxicology, forensic, and clinical labs are often asked ... of THC, most frequently the carboxy form. , ...
... BD Biosciences is pleased to introduce the BD ... (Cat. No. 558142) for the isolation of Treg cells ... isolates Treg cells in two stages. First, negative selection ... cocktail of biotinylated monoclonal antibodies that recognizes antigens expressed ...
... , Introduction ... the cell cycle is commonly used in cell biology since many pharmacological ... here an application that can be used in adherent cells and optionally ... , The cell cycle consists of ...
Cached Biology Technology:Analysis of ()-11-Nor-9-Carboxy-Delta-9-THC in Urine by Negative Ion Electrospray LC/MS/MS 2Analysis of ()-11-Nor-9-Carboxy-Delta-9-THC in Urine by Negative Ion Electrospray LC/MS/MS 3Quantitative Analysis of the Cell Cycle in Imaging Applications 2Quantitative Analysis of the Cell Cycle in Imaging Applications 3Quantitative Analysis of the Cell Cycle in Imaging Applications 4Quantitative Analysis of the Cell Cycle in Imaging Applications 5
(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... Nature, the authors including Dr Ying ... Climate Research say that nitrogen fixation has long ... of many ecosystems particularly boreal and temperate forests ... been significant discrepancies between real-world observations and the theories ...
... has been successful in gaining major European Union ... of biological samples, such as DNA, can be ... Europe. The Centre for Integrated Genomic Medical ... Medicine, is playing a key role in developing ...
... N.Y., June 17 bioMETRX, Inc. (OTC,Bulletin Board: ... today announced that the Handgun Club of America ... are showing great interest in,bioMETRX,s smartTOUCH(TM) bioVAULT 2.0 ... with the touch of a finger, and recognition,taking ...
Cached Biology News:Scientists may have solved an ecological riddle 2Manchester clears first hurdle in €170 million biobank building boom 2bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America 2bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America 3